385 related articles for article (PubMed ID: 19595118)
21. Dextran-polylactide micelles loaded with doxorubicin and DiR for image-guided chemo-photothermal tumor therapy.
Shi Y; Tan R; Yu C; Wan Y
Int J Biol Macromol; 2021 Sep; 187():296-308. PubMed ID: 34310998
[TBL] [Abstract][Full Text] [Related]
22. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin.
Zhang J; Chen XG; Li YY; Liu CS
Nanomedicine; 2007 Dec; 3(4):258-65. PubMed ID: 17962086
[TBL] [Abstract][Full Text] [Related]
23. [VCR-loaded nanoparticles as targeted delivery system for the treatment of orbital adenoid cystic carcinoma].
He YJ; Lin TT; Zhu LM; Luo H; Chang J; Zhang H; Zhang HM
Zhonghua Yan Ke Za Zhi; 2010 Sep; 46(9):795-801. PubMed ID: 21092558
[TBL] [Abstract][Full Text] [Related]
24. PEG-PLA diblock copolymer micelle-like nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations.
Li Y; Qi XR; Maitani Y; Nagai T
Nanotechnology; 2009 Feb; 20(5):055106. PubMed ID: 19417337
[TBL] [Abstract][Full Text] [Related]
25. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Wang C; Wei X; Shao G
Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin release from self-assembled nanoparticles of deoxycholic acid-conjugated dextran.
Jeong YI; Chung KD; Choi KC
Arch Pharm Res; 2011 Jan; 34(1):159-67. PubMed ID: 21468928
[TBL] [Abstract][Full Text] [Related]
27. Effect of molecular weight on the oleoyl-chitosan nanoparticles as carriers for doxorubicin.
Zhang J; Chen XG; Sun GZ; Huang L; Cheng XJ
Colloids Surf B Biointerfaces; 2010 Jun; 77(2):125-30. PubMed ID: 20172698
[TBL] [Abstract][Full Text] [Related]
28. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery.
Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
Biomaterials; 2009 Oct; 30(29):5757-66. PubMed ID: 19643472
[TBL] [Abstract][Full Text] [Related]
29. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
[TBL] [Abstract][Full Text] [Related]
30. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes.
Huang SK; Stauffer PR; Hong K; Guo JW; Phillips TL; Huang A; Papahadjopoulos D
Cancer Res; 1994 Apr; 54(8):2186-91. PubMed ID: 8174126
[TBL] [Abstract][Full Text] [Related]
31. Preparation and anti-tumor efficiency evaluation of doxorubicin-loaded bacterial magnetosomes: magnetic nanoparticles as drug carriers isolated from Magnetospirillum gryphiswaldense.
Sun JB; Duan JH; Dai SL; Ren J; Guo L; Jiang W; Li Y
Biotechnol Bioeng; 2008 Dec; 101(6):1313-20. PubMed ID: 18980188
[TBL] [Abstract][Full Text] [Related]
32. Polyphosphazene nanoparticles for cytoplasmic release of doxorubicin with improved cytotoxicity against Dox-resistant tumor cells.
Zheng C; Xu J; Yao X; Xu J; Qiu L
J Colloid Interface Sci; 2011 Mar; 355(2):374-82. PubMed ID: 21220138
[TBL] [Abstract][Full Text] [Related]
33. Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery.
Lu PL; Chen YC; Ou TW; Chen HH; Tsai HC; Wen CJ; Lo CL; Wey SP; Lin KJ; Yen TC; Hsiue GH
Biomaterials; 2011 Mar; 32(8):2213-21. PubMed ID: 21176954
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of metastatic carcinoma cell growth in livers by poly(I):poly(C)/cationic liposome complex (LIC).
Hirabayashi K; Yano J; Takesue H; Fujiwara N; Irimura T
Oncol Res; 1999; 11(11-12):497-504. PubMed ID: 10905561
[TBL] [Abstract][Full Text] [Related]
35. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R
J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245
[TBL] [Abstract][Full Text] [Related]
36. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
[TBL] [Abstract][Full Text] [Related]
37. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy.
Zhang C; Wang W; Liu T; Wu Y; Guo H; Wang P; Tian Q; Wang Y; Yuan Z
Biomaterials; 2012 Mar; 33(7):2187-96. PubMed ID: 22169820
[TBL] [Abstract][Full Text] [Related]
39. Chitosan oligosaccharide-arachidic acid-based nanoparticles for anti-cancer drug delivery.
Termsarasab U; Cho HJ; Kim DH; Chong S; Chung SJ; Shim CK; Moon HT; Kim DD
Int J Pharm; 2013 Jan; 441(1-2):373-80. PubMed ID: 23174411
[TBL] [Abstract][Full Text] [Related]
40. Glyco-nanoparticles with sheddable saccharide shells: a unique and potent platform for hepatoma-targeting delivery of anticancer drugs.
Chen W; Zou Y; Meng F; Cheng R; Deng C; Feijen J; Zhong Z
Biomacromolecules; 2014 Mar; 15(3):900-7. PubMed ID: 24460130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
